+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ewing's Sarcoma Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Ewing's Sarcoma Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4846466
  • Report
  • September 2019
  • Region: Global
  • 156 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • MORE
Global Ewing's Sarcoma Treatment Market: About this market

The Ewing's sarcoma treatment market analysis considers sales from monotherapy and combination therapy types. Our study also finds the sales of Ewing's sarcoma treatment in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high efficacy of combination therapy in treating Ewing's sarcoma will play a significant role in the combination therapy segment to maintain its market position. Also, our global Ewing's sarcoma treatment market report looks at factors such as the growing awareness about and funding for Ewing's sarcoma, regulatory incentives, and financial assistance programs and reimbursement schemes. However, lack of approved therapies for Ewing's sarcoma, absence of predictive biomarkers in Ewing's sarcoma, and side-effects of chemotherapy may hamper the growth of the Ewing's sarcoma treatment industry over the forecast period.

Global Ewing's Sarcoma Treatment Market: Overview

Financial assistance programs and reimbursement schemes

The increasing cost of therapeutics for the treatment of various indications is encouraging governments of various countries and pharmaceutical vendors to introduce several financial assistance programs and reimbursement schemes. There are several drug assistance programs that offer payment limitation programs for costly medications such as chemotherapeutics. GlaxoSmithKline, Merck, and Pfizer are some of the prominent vendors providing prescription drug assistance programs to patients. Such assistance programs increase the patient adherence to drug treatment which will eventually lead to the expansion of the global Ewing's sarcoma treatment market at a CAGR of almost 6% during the forecast period.

Emergence of regenerative therapies

Regenerative medicines, including gene therapy, are gaining traction in the market. This is encouraging several pharmaceutical companies to study and develop a gene therapy to treat metastatic Ewing's sarcoma and recurrent Ewing's tumors. The new therapeutic methods help in minimizing tumor cell proliferation in advance Ewing's sarcoma. For instance, Gradalis is conducting a Phase I clinical trial to evaluate pbi-shRNA EWS/FLI1 Type 1 LPX, an anti-stathmin gene therapy.The growing focus on advancing regenerative medicines in clinical phases is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Ewing's sarcoma treatment market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewing's sarcoma treatment manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, Ewing's sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS
  • Strong pipeline
  • Emergence of regenerative therapies
  • Advent of CRISPR-Cas9 technology
PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product Overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amneal Pharmaceuticals Inc. - Vendor overview
Exhibit 49: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 50: Amneal Pharmaceuticals Inc. - Organizational developments
Exhibit 51: Amneal Pharmaceuticals Inc. - Segment focus
Exhibit 52: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 53: Amneal Pharmaceuticals Inc. - Key customers
Exhibit 54: Baxter International Inc. - Vendor overview
Exhibit 55: Baxter International Inc. - Business segments
Exhibit 56: Baxter International Inc. - Organizational developments
Exhibit 57: Baxter International Inc. - Segment focus
Exhibit 58: Baxter International Inc. - Key offerings
Exhibit 59: Baxter International Inc. - Key customers
Exhibit 60: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 61: Bristol-Myers Squibb Co. - Business segments
Exhibit 62: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 63: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 64: Bristol-Myers Squibb Co. - Key offerings
Exhibit 65: Bristol-Myers Squibb Co. - Key customers
Exhibit 66: Eli Lilly and Co. - Vendor overview
Exhibit 67: Eli Lilly and Co. - Business segments
Exhibit 68: Eli Lilly and Co. - Organizational developments
Exhibit 69: Eli Lilly and Co. - Geographic focus
Exhibit 70: Eli Lilly and Co. - Segment focus
Exhibit 71: Eli Lilly and Co. - Key offerings
Exhibit 72: Eli Lilly and Co. - Key customers
Exhibit 73: Merck & Co. Inc. - Vendor overview
Exhibit 74: Merck & Co. Inc. - Business segments
Exhibit 75: Merck & Co. Inc. - Organizational developments
Exhibit 76: Merck & Co. Inc. - Geographic focus
Exhibit 77: Merck & Co. Inc. - Segment focus
Exhibit 78: Merck & Co. Inc. - Key offerings
Exhibit 79: Merck & Co. Inc. - Key customers
Exhibit 80: Mylan NV - Vendor overview
Exhibit 81: Mylan NV - Product segments
Exhibit 82: Mylan NV - Organizational developments
Exhibit 83: Mylan NV - Geographic focus
Exhibit 84: Mylan NV - Segment focus
Exhibit 85: Mylan NV - Key offerings
Exhibit 86: Mylan NV - Key customers
Exhibit 87: Novartis AG - Vendor overview
Exhibit 88: Novartis AG - Business segments
Exhibit 89: Novartis AG - Organizational developments
Exhibit 90: Novartis AG - Geographic focus
Exhibit 91: Novartis AG - Segment focus
Exhibit 92: Novartis AG - Key offerings
Exhibit 93: Novartis AG - Key customers
Exhibit 94: Pfizer Inc. - Vendor overview
Exhibit 95: Pfizer Inc. - Business segments
Exhibit 96: Pfizer Inc. - Organizational developments
Exhibit 97: Pfizer Inc. - Geographic focus
Exhibit 98: Pfizer Inc. - Segment focus
Exhibit 99: Pfizer Inc. - Key offerings
Exhibit 100: Pfizer Inc. - Key customers
Exhibit 101: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 107: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 113: Validation techniques employed for market sizing
Exhibit 114: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll